Omega Healthcare Investors
Omega Healthcare Investors' revenue rose 13.2% to $1.2 billion in fiscal 2025. Its net margin was 49.6%, up from 38.6% a year earlier. Free cash flow was $798 million, up 12.1%. It paid out $780 million in dividends and buybacks, 98% of free cash flow. The diluted share count rose 12.8%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share grew 0.2% a year and net income 4.9% a year, as new shares raised the share count by 51% and diluted each share's earnings.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Omega Healthcare Investors yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Omega Healthcare Investors' 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Omega Healthcare Investors' fiscal 2025 free cash flow of $798M, net cash of −$4.2B at December 31, 2025 and 305 million diluted shares, from its filings. The scenarios are fitted to Omega Healthcare Investors: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 10.7% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 9% for a business of moderate risk (Health Care REITs); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $47.01
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Omega Healthcare Investors' earnings per share of $2.80 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 28.1×, the middle of Omega Healthcare Investors' own P/E today, its peers' median and its sector's median (the Real Estate median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 10%, 9% and 8%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $47.01
- Value at this multiple, against the last close
- —
- Omega Healthcare Investors' P/E at the last close
- 16.8×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| American Healthcare REITAHR | $53.55 | $0.68 | 78.7× |
| Sabra Health Care REITSBRA | $19.78 | $0.26 | 76.1× |
| Healthpeak PropertiesDOC | $19.36 | $0.35 | 55.3× |
| Omega Healthcare InvestorsOHI | $47.01 | $2.80 | 16.8× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 20 | 297 | 443 | 518 | 27 |
| Debt incl. finance leases | 5,254 | 5,287 | 5,067 | 4,839 | 4,256 |
| Net debt (negative means net cash) | 5,233 | 4,990 | 4,624 | 4,321 | 4,229 |
| Net debt to EBITDA | 5.3x | 5.0x | 5.7x | 4.5x | 3.6x |
| Debt to equity | 1.3x | 1.5x | 1.4x | 1.1x | 0.8x |
| Interest coverage | 2.8x | 2.9x | 2.1x | 2.9x | 3.9x |
| Current ratio | — | — | — | — | — |
| Quick ratio | — | — | — | — | — |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, 2 insiders bought $1.4 million of Omega Healthcare Investors shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2025 | Vikas GuptaChief Investment Officer | Bought | 11,500 | $42.97 | $494,155 | Form 4 |
| Nov 5, 2025 | Pickett C TaylorChief Executive Officer, Director | Bought | 20,000 | $43.14 | $862,800 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | — | — | — |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
| Accruals ratio | −4.1% | −3.6% | −2.9% |
Compare
Put Omega Healthcare Investors side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Omega Healthcare Investors | FY25 | 13.2% | — | 67.0% | 8.8% | 3.6x | — | |
| Healthcare Realty Trust | FY25 | −6.9% | — | 10.8% | — | — | — | Compare |
| Sabra Health Care REIT | FY25 | 10.2% | — | — | 5.1% | 5.4x | — | Compare |
| American Healthcare REIT | FY25 | 9.2% | 18.4% | — | — | — | — | Compare |
| Healthpeak Properties | FY25 | 4.5% | — | 12.7% | 3.2% | 5.7x | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 901 | 908 | 882 | 929 | 892 | 1,063 | 878 | 950 | 1,051 | 1,190 |
| Revenue growth | — | 0.8% | −2.9% | 5.3% | −3.9% | 19.1% | −17.4% | 8.1% | 10.7% | 13.2% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 560 | 315 | 498 | 552 | — | — | — | — | — | — |
| Net income | 383 | 105 | 294 | 352 | 164 | 428 | 439 | 242 | 406 | 590 |
| Diluted EPS (US$) | 1.90 | 0.51 | 1.40 | 1.58 | 0.70 | 1.75 | 1.80 | 1.00 | 1.55 | 1.94 |
| Diluted shares (millions) | 202 | 207 | 210 | 222 | 235 | 244 | 244 | 250 | 270 | 305 |
| Cash flow | ||||||||||
| Cash from operations | 625 | 578 | 499 | 554 | 708 | 722 | 626 | 618 | 749 | 879 |
| Capital expenditure | 40 | 38 | 30 | 53 | 31 | 45 | 47 | 38 | 38 | 81 |
| Free cash flow | 584 | 540 | 470 | 501 | 677 | 677 | 579 | 580 | 712 | 798 |
| Dividends paid | 453 | 503 | 529 | 564 | 612 | 638 | 633 | 644 | 685 | 780 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 142 | 0 | 0 | 0 |
| Acquisitions | 1,023 | 413 | 106 | 60 | 5 | 604 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 14 | 15 | 16 | 15 | 19 | 21 | 27 | 35 | 37 | 44 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 94 | 86 | 10 | 24 | 164 | 20 | 297 | 443 | 518 | 27 |
| Debt incl. finance leases | 4,367 | 4,572 | 4,541 | 5,136 | 5,169 | 5,254 | 5,287 | 5,067 | 4,839 | 4,256 |
| Total assets | 8,949 | 8,773 | 8,591 | 9,796 | 9,497 | 9,638 | 9,405 | 9,117 | 9,898 | 10,049 |
| Total liabilities | 4,737 | 4,885 | 4,826 | 5,460 | 5,461 | 5,530 | 5,602 | 5,355 | 5,167 | 4,609 |
| Shareholders' equity | 3,859 | 3,555 | 3,444 | 4,135 | 3,842 | 3,907 | 3,609 | 3,575 | 4,537 | 5,181 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 62.2% | 34.7% | 56.4% | 59.4% | — | — | — | — | — | — |
| Net margin | 42.6% | 11.6% | 33.3% | 37.9% | 18.3% | 40.3% | 50.0% | 25.5% | 38.6% | 49.6% |
| Free cash flow margin | 64.9% | 59.5% | 53.3% | 53.9% | 75.9% | 63.7% | 65.9% | 61.0% | 67.7% | 67.0% |
| Return on capital | 6.9% | 3.6% | 5.9% | 6.2% | 4.0% | 7.0% | 7.3% | 5.6% | 7.3% | 8.8% |
| Return on equity | 10.1% | 2.8% | 8.4% | 9.3% | 4.1% | 11.1% | 11.7% | 6.7% | 10.0% | 12.2% |
| Return on assets | 4.5% | 1.2% | 3.4% | 3.8% | 1.7% | 4.5% | 4.6% | 2.6% | 4.3% | 5.9% |
| Net debt to EBITDA | 5.2x | 7.4x | 5.8x | 6.0x | 7.0x | 5.3x | 5.0x | 5.7x | 4.5x | 3.6x |